IL281143B2 - Salts and crystalline forms of a positive allosteric modulator of GABAA - Google Patents

Salts and crystalline forms of a positive allosteric modulator of GABAA

Info

Publication number
IL281143B2
IL281143B2 IL281143A IL28114321A IL281143B2 IL 281143 B2 IL281143 B2 IL 281143B2 IL 281143 A IL281143 A IL 281143A IL 28114321 A IL28114321 A IL 28114321A IL 281143 B2 IL281143 B2 IL 281143B2
Authority
IL
Israel
Prior art keywords
compound
exhibits
xrpd
peaks
theta
Prior art date
Application number
IL281143A
Other languages
English (en)
Hebrew (he)
Other versions
IL281143B1 (en
IL281143A (en
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of IL281143A publication Critical patent/IL281143A/en
Publication of IL281143B1 publication Critical patent/IL281143B1/en
Publication of IL281143B2 publication Critical patent/IL281143B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
IL281143A 2018-08-31 2019-08-30 Salts and crystalline forms of a positive allosteric modulator of GABAA IL281143B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725805P 2018-08-31 2018-08-31
US16/517,369 US10562930B1 (en) 2018-08-31 2019-07-19 Salts and crystal forms of GABAA positive allosteric modulator
PCT/US2019/049103 WO2020047434A1 (en) 2018-08-31 2019-08-30 Salts and crystal forms of gabaa positive allosteric modulator

Publications (3)

Publication Number Publication Date
IL281143A IL281143A (en) 2021-04-29
IL281143B1 IL281143B1 (en) 2024-12-01
IL281143B2 true IL281143B2 (en) 2025-04-01

Family

ID=69528249

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281143A IL281143B2 (en) 2018-08-31 2019-08-30 Salts and crystalline forms of a positive allosteric modulator of GABAA

Country Status (13)

Country Link
US (4) US10562930B1 (enExample)
EP (2) EP3710465B1 (enExample)
JP (3) JP7199739B2 (enExample)
KR (1) KR102845326B1 (enExample)
CN (1) CN113473991A (enExample)
AU (1) AU2019333310B8 (enExample)
BR (1) BR112021003727A2 (enExample)
CA (1) CA3111193A1 (enExample)
IL (1) IL281143B2 (enExample)
MA (1) MA50921A (enExample)
MX (1) MX2021002382A (enExample)
TW (2) TWI850138B (enExample)
WO (1) WO2020047434A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061527A1 (en) * 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
AU2019397565A1 (en) * 2018-12-14 2021-07-08 Praxis Precision Medicines, Inc. Methods for the treatment of depression
PE20221911A1 (es) 2020-03-25 2022-12-23 Sage Therapeutics Inc Uso de agentes para el tratamiento de condiciones respiratorias
WO2022006541A1 (en) * 2020-07-02 2022-01-06 Praxis Precision Medicines, Inc. Methods for the treatment of adjustment disorder
WO2022177718A1 (en) 2021-02-18 2022-08-25 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
JP2024506942A (ja) * 2021-02-18 2024-02-15 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態
WO2022231309A1 (ko) 2021-04-27 2022-11-03 경북대학교 산학협력단 저분자 콜라겐을 유효성분으로 포함하는 근감소증의 예방 또는 개선용 식품 조성물 및 약학적 조성물
WO2023159035A1 (en) 2022-02-16 2023-08-24 Sage Therapeutics, Inc. Neuroactive steroids for treatment of cns-related disorders
WO2023164386A1 (en) * 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066614A1 (en) * 1999-04-29 2000-11-09 Purdue Pharma Ltd. 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY
WO2006131392A1 (en) * 2005-06-09 2006-12-14 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU698834B2 (en) * 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
KR19990022323A (ko) 1995-06-06 1999-03-25 씨. 랜 낸시 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
CN1688288A (zh) * 2002-08-05 2005-10-26 巴克斯特国际公司 具有多晶型控制的亚微米粒度颗粒的制备和新多晶型伊曲康唑
WO2004072079A1 (en) 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
WO2005007600A2 (en) 2003-07-11 2005-01-27 Eisai Co., Ltd. Novel methods using aminobenzoic acid compounds
EP1656353B1 (en) 2003-08-14 2010-01-27 F. Hoffmann-La Roche Ag Gabanergic modulators
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060074059A1 (en) 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007111880A2 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
US20090074677A1 (en) 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
CN103936716B (zh) * 2009-04-23 2016-09-07 施万呼吸有限责任公司 具蕈毒碱受体拮抗剂和β2肾上腺素受体激动剂活性的二酰胺化合物
MX2012009821A (es) * 2010-02-24 2012-10-09 Univ Ramot Formas cristalinas de la sal de tri-mesilato de perfenazina-gaba y proceso para producirlas.
SG190224A1 (en) * 2010-11-11 2013-06-28 Akron Molecules Gmbh Compounds and methods for treating pain
WO2013006857A1 (en) 2011-07-07 2013-01-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
PL3024458T3 (pl) 2013-07-24 2018-08-31 Commissariat à l'énergie atomique et aux énergies alternatives Zastosowanie flekainidu jako środka anty-koneksynowego oraz sposób wzmacniania efektów działania leku psychotropowego
AU2015296117B2 (en) * 2014-08-01 2019-05-16 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Crystalline free bases of C-Met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016061527A1 (en) * 2014-10-16 2016-04-21 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US10420773B2 (en) 2017-09-26 2019-09-24 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with etifoxine
AU2018364659A1 (en) 2017-11-10 2020-05-28 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating genetic epileptic disoders
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
AU2019397565A1 (en) * 2018-12-14 2021-07-08 Praxis Precision Medicines, Inc. Methods for the treatment of depression
CN113226326B (zh) 2018-12-17 2024-09-20 细胞内治疗公司 有机化合物
EP3934655A4 (en) 2019-03-04 2022-12-21 Praxis Precision Medicines, Inc. PERIMENOPAUSE AND MENOPAUSE TREATMENT METHODS
WO2020185710A1 (en) 2019-03-08 2020-09-17 Alairion, Inc. Method for treating sleep fragmentation disorders using neurosteroid positive allosteric modulators of the gabaa receptor
WO2021025985A1 (en) 2019-08-02 2021-02-11 Praxis Precision Medicines, Inc. Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression
AU2020358002A1 (en) 2019-10-02 2022-04-21 Praxis Precision Medicines, Inc. Combinations of GABA-A receptor positive allosteric modulators and NMDA antagonists, NMDA negative allosteric modulators or NMDA partial agonists
WO2021168106A1 (en) 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
WO2022006541A1 (en) 2020-07-02 2022-01-06 Praxis Precision Medicines, Inc. Methods for the treatment of adjustment disorder
WO2022040545A1 (en) 2020-08-20 2022-02-24 Intra-Cellular Therapies, Inc. Organic compounds
JP2024506942A (ja) 2021-02-18 2024-02-15 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態
CN117715641A (zh) 2021-04-26 2024-03-15 普拉西斯精密医药公司 用神经活性类固醇进行治疗的方法
WO2023159094A2 (en) 2022-02-16 2023-08-24 Praxis Precision Medicines, Inc. PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE
WO2023211856A1 (en) 2022-04-26 2023-11-02 Praxis Precision Medicines, Inc. Methods for the treatment of neurological disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066614A1 (en) * 1999-04-29 2000-11-09 Purdue Pharma Ltd. 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY
WO2006131392A1 (en) * 2005-06-09 2006-12-14 Euro-Celtique S.A. Pharmaceutical compositions of a neuroactive steroid and uses thereof

Also Published As

Publication number Publication date
US10562930B1 (en) 2020-02-18
AU2019333310A8 (en) 2025-04-17
EP4458357A2 (en) 2024-11-06
IL281143B1 (en) 2024-12-01
WO2020047434A1 (en) 2020-03-05
US20240140985A1 (en) 2024-05-02
US20200071350A1 (en) 2020-03-05
KR102845326B1 (ko) 2025-08-12
MX2021002382A (es) 2021-08-11
EP3710465B1 (en) 2024-08-14
US20200255471A1 (en) 2020-08-13
EP3710465A4 (en) 2020-09-23
JP2025020120A (ja) 2025-02-12
TWI823999B (zh) 2023-12-01
JP2021504297A (ja) 2021-02-15
EP3710465A1 (en) 2020-09-23
AU2019333310B2 (en) 2024-11-21
MA50921A (fr) 2020-09-23
IL281143A (en) 2021-04-29
CN113473991A (zh) 2021-10-01
BR112021003727A2 (pt) 2021-05-25
EP4458357A3 (en) 2024-12-18
US10927141B2 (en) 2021-02-23
JP7199739B2 (ja) 2023-01-06
KR20210054546A (ko) 2021-05-13
JP2023036708A (ja) 2023-03-14
AU2019333310B8 (en) 2025-04-17
TW202408461A (zh) 2024-03-01
US20220024967A1 (en) 2022-01-27
AU2019333310A1 (en) 2021-04-08
TW202024108A (zh) 2020-07-01
US12404297B2 (en) 2025-09-02
CA3111193A1 (en) 2020-03-05
TWI850138B (zh) 2024-07-21

Similar Documents

Publication Publication Date Title
US12404297B2 (en) Salts and crystal forms of GABA-A positive allosteric modulator
NO326148B1 (no) Tartratsalter av 5,8,14-triazatetracyklo (10.3.1.0<O>2,11</O>.0<O>4.9</O>)-heksadeka-2 (11),3,5,7,9-pentaen, samt anvendelse derav og farmasoytisk blanding derav
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
EP4582145A2 (en) Solid state forms of ixazomib citrate
US11434226B2 (en) Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof
HK40118203A (en) Salts and crystal forms of gabaa positive allosteric modulator
HK40037178A (en) Salts and crystal forms of gabaa positive allosteric modulator
HK40037178B (en) Salts and crystal forms of gabaa positive allosteric modulator